Beddows, Cait A. https://orcid.org/0009-0007-8560-0329
Shi, Feiyue https://orcid.org/0009-0007-8785-3813
Horton, Anna L. https://orcid.org/0000-0002-0140-0757
Dalal, Sagar https://orcid.org/0000-0003-2838-1901
Zhang, Ping
Ling, Chang-Chun
Yong, V. Wee https://orcid.org/0000-0002-2600-3563
Loh, Kim
Cho, Ellie https://orcid.org/0000-0002-2932-1890
Karagiannis, Chris https://orcid.org/0009-0007-7063-0162
Rose, Adam J. https://orcid.org/0000-0001-9132-8244
Montgomery, Magdalene K.
Gregorevic, Paul https://orcid.org/0000-0002-7418-8945
Watt, Matthew J. https://orcid.org/0000-0003-4064-4188
Packer, Nicolle H. https://orcid.org/0000-0002-7532-4021
Parker, Benjamin L. https://orcid.org/0000-0003-1818-2183
Brown, Robyn M.
Moh, Edward S. X. https://orcid.org/0000-0003-4289-0147
Dodd, Garron T. https://orcid.org/0000-0002-7554-4876
Article History
Received: 26 May 2022
Accepted: 7 August 2024
First Online: 18 September 2024
Competing interests
: G.T.D, C.A.B. and F.S. hold method-of-use patents for treating insulin resistance and associated disorders (patent numbers WO2024086895 and WO2024113004).